REVIEW ARTICLE

Nanocarrier-based formulations: Regulatory Challenges, Ethical and Safety Considerations in Pharmaceuticals

Sunil L. Kardani, Avinash K. Seth

Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India

Abstract

Nano-formulations represent an innovative approach in pharmaceuticals, offering enhanced drug delivery, improved therapeutic efficacy, and reduced side effects. This abstract delves into the regulatory, ethical, and safety facets associated with these formulations. Regulatory challenges form a pivotal aspect, encompassing the need for specific guidelines tailored to nano-based drugs. Addressing these challenges involves a comprehensive evaluation of characterization techniques, stability assessments, and establishing standardized protocols for manufacturing and quality control. Regulatory bodies worldwide face the task of developing adaptable frameworks to streamline approval processes, ensuring efficacy and safety while expediting the translation of research into clinical applications. Ethical considerations in nano-formulations revolve around informed consent, risk-benefit assessments, and equitable access to these advancements. Balancing the potential benefits against potential risks and ensuring transparent communication with stakeholders becomes imperative in ethical decision-making. Moreover, equitable distribution and affordability of these advanced therapies pose ethical dilemmas in healthcare systems globally. Safety considerations encompass a thorough understanding of nanomaterial interactions within the biological milieu, potential toxicity, and long-term effects. Robust safety assessments, including *in vitro* and *in vivo* studies, are essential to ascertain biocompatibility and mitigate unforeseen risks associated with nanocarriers. Continuous monitoring and postmarket surveillance further ensure ongoing safety evaluation. Collaborative efforts among regulatory agencies, researchers, health-care providers, and ethicists are pivotal to harness the potential of these formulations while ensuring patient safety, ethical practice, and regulatory.

Key words: Ethical considerations, nanocarrier-based formulations, regulatory challenges, safety assessment

INTRODUCTION TO NANOCARRIER-BASED FORMULATIONS

Nano-formulations have revolutionized pharmaceuticals by facilitating the precise and efficient delivery of therapeutic substances. These formulations employ nanosized carriers to encase drugs, genes, or imaging agents, offering numerous advantages compared to traditional delivery systems. Their small size, expand the surface area to volume ratio, and customizable surface features grant precise control over drug release rates and absorption by cells. These carriers, spanning liposomes, polymeric nanoparticles, dendrimers, micelles, and inorganic nanoparticles, such as quantum dots and gold nanoparticles, each boast unique benefits in terms of drug capacity, stability, and compatibility with various therapies.[1] Their application resolves several issues encountered in conventional drug delivery, enhancing the solubility of poorly water-soluble medications, safeguarding drugs from degradation, and allowing sustained or triggered release at specific sites, thereby minimizing systemic side effects.[2] In addition, they enable targeted delivery to specific cells, tissues, or organs, reducing off-target effects and heightening therapeutic efficacy. By attaching ligands, antibodies, or peptides, these carriers can precisely target diseased cells displaying unique biomarkers.[3] Beyond therapeutics, nano-formulations extend to include imaging agents for diagnostics. Encapsulation of contrast agents enhances imaging techniques, such as MRI, CT scans, and

Address for correspondence:
Sunil L. Kardani, Ph.D Scholar, Department of Pharmacy, Sumandeep Vidyapeeth deemed to be a University
Piparia, Vadodara, Gujarat, India.
E-mail: sunilkardani@yahoo.co.in

Received: 26-04-2024
Revised: 13-06-2024
Accepted: 23-06-2024

fluorescence imaging, improving resolution and specificity.[4] These formulations hold tremendous promise, challenges persist in their clinical translation, encompassing scalability, reproducibility, safety, and regulatory hurdles that must be overcome for widespread adoption.[5]

OVERVIEW OF NANOTECHNOLOGY

Nanotechnology has transformed the landscape of drug delivery methodologies, introducing inventive strategies to enhance the effectiveness, safety, and precision of therapeutic substances. At the nanoscopic level, materials possess distinctive characteristics that can be customized to precisely target drugs, regulate their release, and improve their availability within the body. This advancement has resulted in the creation of diverse platforms that overcome the limitations inherent in conventional drug delivery systems. Nanotechnology-driven drug delivery systems encompass an extensive range of nanocarriers, including liposomes, polymeric nanoparticles, dendrimers, micelles, and inorganic nanoparticles. These carriers offer a flexible foundation for enclosing drugs, genes, or imaging agents, safeguarding them from deterioration, enabling regulated release, and facilitating their transportation to specific sites where they exert their action.

COMPARISON WITH CONVENTIONAL DRUG DELIVERY SYSTEMS

Nano-based formulations represent a paradigm shift from conventional drug delivery systems by offering precise targeting and controlled release of therapeutic agents. They enhance drug stability, solubility, and bioavailability while minimizing systemic toxicity and side effects through their nanoscale size. In contrast, conventional drug delivery systems often rely on bulkier carriers or routes that lack specificity, resulting in lower drug efficacy, higher required doses, and increased potential for adverse effects. Nano-based approaches thus promise more efficient and safer drug delivery strategies, potentially transforming treatment outcomes across various medical fields. Comparision of nano based formulation and conventional drug delivery systems is given in Table 1.

CHALLENGES AND FUTURE DIRECTIONS

- Addressing challenges, such as scalability, toxicity, and regulatory considerations is crucial in advancing nanocarrier-based formulations for clinical translation.[6]
- Scalability: Scalability concerns are addressed by optimizing formulation processes, employing scalable manufacturing techniques, and ensuring reproducibility without compromising the quality and properties of nanocarriers.[7]
- Toxicity mitigation: Researchers focus on minimizing toxicity through surface modifications, biocompatible materials, and thorough toxicity assessments using *in vitro* and *in vivo* models, ensuring safety profiles before clinical translation.[8]
- Regulatory considerations: Adhering to regulatory guidelines such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) are toxicological assessments, and ensure manufacturing consistency to meet regulatory requirements.[9]
- Biocompatibility and immunogenicity: Addressing concerns regarding immune responses, nanocarriers are designed to exhibit biocompatibility, minimize immunogenicity, and undergo thorough preclinical evaluations for safety and efficacy.[10]
- Long-term stability and shelf life: Nanocarriers are designed for long-term stability, and stability testing under various conditions is performed to ascertain shelf life, ensuring consistent performance over time. Addressing these challenges involves a multidisciplinary approach, integrating material science, pharmaceutical development, and regulatory compliance to ensure the safe and effective translation of nanocarrier-based formulations from bench to bedside.[11]
- Nanocarrier-based formulations hold immense potential across diverse medical fields, paving the way for transformative advancements. Here are the prospects and potential applications in several medical domains:
- Cancer therapy: Nanocarriers offer targeted drug delivery, minimizing systemic toxicity while enhancing therapeutic efficacy in cancer treatment. Future applications include personalized medicine, combination therapies, and overcoming multidrug resistance.[12]
- Neurodegenerative diseases: Nanocarriers designed to cross the blood–brain barrier hold promise for delivering therapeutics to treat neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, potentially revolutionizing treatments.[13]
- Infectious diseases: Nanocarriers offer targeted and sustained release of antiviral agents, antibiotics, or vaccines for combating infectious diseases. Future applications include addressing antibiotic resistance and enhancing vaccine delivery.[14]
- Regenerative medicine: Nanocarriers facilitate the targeted delivery of growth factors, stem cells, and bioactive molecules for tissue regeneration and repair. Prospects involve enhancing organ regeneration and tissue engineering.[15]
- Diagnostic imaging: Nano-based contrast agents enable highly sensitive and specific imaging modalities for early disease detection and precise diagnostics, promising advancements in personalized and molecular imaging.[16]
- Drug delivery to the eye: Nanocarriers can improve ocular drug delivery, targeting therapies for conditions, such as age-related macular degeneration, glaucoma, and ocular infections.[17]

Table 1: Comparison of convention delivery system versus nanotechnology-based delivery system[5]

Sr. No.	Ideal drug characteristics	Conventional systems	Nanotechnology-based drug delivery systems
1	Any type of physical state	Yes	Yes
2	Independent on dosage	Yes	Yes
3	Scalable system	No	Yes
4	Affordability for patients in terms of material usage	No	Yes
5	Ingredients used are abundant and freely available	No	Possible
6	Non-toxic, biocompatible, and biodegradable	No	Possible
7	No side effects	No	Possible
8	Selectivity in its action	No	Possible
9	The rate of release is instantaneous and controllable	No	Possible
10	Drug release has no relationship with the drug action	No	Possible
11	Drug release is as per the required therapeutic amount	No	Yes
12	No carrier is required to take drug to the reaction site	No	Yes
13	The delivery system should be easy, simple, and cost-effective	No	Possible
14	Drugs should be easily eliminated from the body by simple metabolic processes after its action	No	Possible
15	Drugs will not get accumulated in any part of the body causing inflammation	No	Possible
16	100% effective in curing the disease	No	Possible
17	100% safe for the living body	No	Possible
18	Shows a broad spectrum of efficacy	No	Possible
19	Cures the disease completely	Possible	Possible
20	Cures diseases immediately	No	Possible
21	Produces no byproducts	No	Possible
22	No repetition of the same disease again	No	Possible
23	No therapies and rest are required after recovery	No	Possible
24	No side effects	No	Possible
25	No environmental harm and degradation	No	Possible
26	Location independence	Possible	Yes
27	Solutions to all types of health problems	No	Possible

CLINICAL TRANSLATION AND COMMERCIAL VIABILITY

- The progress in clinical trials and the potential for commercialization of carrier indicate promising advancements in translating these technologies from the laboratory to real-world applications.
- Clinical trials progress: Many nanocarriers have advanced to clinical trials across various therapeutic areas, showcasing safety, efficacy, and targeted delivery. Clinical studies evaluate these formulations' performance, pharmacokinetics, and therapeutic outcomes in humans.
- Cancer therapies: Several nano-based drugs for cancer therapy have entered clinical trials, demonstrating enhanced efficacy and reduced side effects. Examples include liposomal doxorubicin (Doxil) and Abraxane (albumin bound paclitaxel).[18]
- Targeted drug delivery: Clinical trials explore targeted delivery systems, utilizing nanoparticles to deliver drugs specifically to diseased tissues while minimizing off-target effects, representing a paradigm shift in drug delivery.[19]
- Emerging therapeutic areas: Clinical investigations in nanomedicine extend beyond cancer to include neurological disorders, infectious diseases, cardiovascular ailments, and regenerative medicine, indicating the versatility and potential applications of nano-based formulations.[20]
- Regulatory approval and commercialization: Several nano-based drugs have received regulatory approval and entered the market, paving the way for commercialization. This includes products, such as AmBisome, a liposomal formulation of amphotericin B for fungal infections.[21]
- Commercialization potential: The expanding pipeline of nano-based drugs in clinical trials indicates the growing

interest of pharmaceutical companies, highlighting the commercial potential and market viability of these formulations.

CLINICAL TRANSLATION AND COMMERCIAL VIABILITY

- The implementation of nanocarrier-based formulations faces several regulatory hurdles before achieving widespread adoption. To navigate these challenges and ensure their safe and effective use, certain steps are crucial.
- Regulatory approval pathways: Understanding and complying with regulatory frameworks (such as FDA and EMA) for drug approval is vital. Nano-based formulations require rigorous preclinical and clinical evaluations to demonstrate safety, efficacy, and manufacturing consistency.
- Toxicological assessment: Thorough toxicological evaluations are essential to assess the potential adverse effects of nanocarriers. Comprehensive studies investigating biodistribution, biocompatibility, and toxicity are crucial.
- Standardization and quality control: Standardized manufacturing processes and quality control measures ensure batch-to-batch consistency, stability, and reproducibility, critical for regulatory approval and commercialization.[22]
- Characterization and analytical methods: Robust analytical methods and comprehensive characterization techniques are necessary to evaluate the physicochemical properties, stability, and drug release kinetics of nanocarriers, supporting regulatory submissions.[23]
- Risk assessment and risk management: Conducting risk assessments to identify potential hazards associated with nanomaterials and implementing risk management strategies are crucial steps in regulatory compliance.[24]
- Regulatory engagement and collaboration: Engaging with regulatory agencies, fostering collaborations, and proactive communication throughout the development process facilitate understanding and compliance with evolving regulatory requirements.[25]

ETHICAL AND SAFETY CONSIDERATIONS

- Nano-based drug delivery systems present ethical implications and safety concerns that warrant attention in their development and application.

Ethical implications

a. Unforeseen risks: The novelty of nanotechnology in drug delivery raises concerns about unforeseen risks and effects on human health and the environment.[26]
b. Regulatory oversight: Addressing ethical considerations involves ensuring robust regulatory oversight to assess risks and benefits, balancing innovation with safety.[27]
c. Equitable access: Ensuring equitable access to nano-based therapies raises ethical questions regarding affordability and availability for all socioeconomic groups.[28]

Safety concerns

a. Nanomaterial toxicity: Certain nanomaterials might exhibit unique toxicological profiles, necessitating comprehensive safety assessments.
b. Bioaccumulation and biodistribution: Understanding nano material bioaccumulation and distribution within the body is crucial to mitigate potential effects.
c. Immunogenicity and allergic responses: Nanomaterials might trigger immune responses or allergic reactions, necessitating evaluation for immunogenic potential.[29]
d. Environmental impact: Disposal of nano-based materials and their potential environmental impact raises concerns about ecological safety.[30]

- Mitigating potential risks and ensuring the safety of nanocarrier-based formulations involves several strategic approaches aimed at thorough evaluation, risk management, and responsible development.

Risk assessment and evaluation

a. Comprehensive toxicity studies: Conduct extensive *in vitro* and *in vivo* toxicity assessments to understand the potential adverse effects of nanomaterials.
b. Biodistribution and metabolism studies: Investigate the fate of nanocarriers within the body to evaluate their distribution and potential accumulation.

Material and formulation optimization

a. Use of biocompatible materials: Prioritize the use of biocompatible and nontoxic nanomaterials to reduce risks of adverse reactions.
b. Surface modifications: Modify nanocarrier surfaces to minimize immunogenicity and enhance biocompatibility.

Regulatory compliance and oversight

a. Adherence to guidelines: Comply with regulatory standards and guidelines for thorough evaluation and approval of nano-based formulations.

- Risk management plans: Develop risk management strategies to address identified hazards and potential risks.

Ethical and societal considerations

a. Transparency and communication: Foster transparent communication regarding risks, benefits, and uncertainties associated with nano-based formulations.

b. Stakeholder engagement: Engage stakeholders, including the public, healthcare professionals, and policymakers, in discussions about nano materials' safety and implications.

Continued monitoring and research

a. Postmarket surveillance: Implement monitoring systems to assess long-term safety and monitor any adverse effects post commercialization.[31]
b. Advancements in safety assessment: Continue research efforts to develop improved safety assessment methods for nano-based materials.

RECOMMENDATIONS

Research directions

a. Understanding biological interactions: Investigate the nano bio interface to comprehend interactions between nanomaterials and biological systems, aiding in safer design and application.
b. Long-term safety assessment: Conduct comprehensive studies to assess the long-term effects and potential risks associated with nanomaterials for better risk management.

Technological advancements

a. Smart drug delivery systems: Develop intelligent nanocarriers capable of triggered or responsive drug release based on specific stimuli, enhancing precision and efficacy.[32]
b. Multifunctional nano platforms: Design nanocarriers with multiple functionalities, such as imaging, therapy, and targeting, for improved clinical applications.[33]

Clinical applications

a. Personalized medicine strategies: Explore nanotechnology for personalized therapies, considering patient-specific factors for tailored drug delivery.
b. Combination therapies: Investigate the potential of nanocarriers in facilitating combination therapies for synergistic effects and overcoming drug resistance.

Regulatory and translation focus

a. Regulatory standardization: Establish standardized protocols and regulatory guidelines specific to nanomaterials for efficient evaluation and approval.
b. Clinical translation and commercialization: Focus on strategies for effective translation from bench to bedside, addressing scalability and commercial viability.

Integration of multidisciplinary efforts

a. Collaborative research initiatives: Encourage interdisciplinary collaborations between scientists, clinicians, engineers, and regulatory bodies to expedite advancements.[34]
b. Real-time monitoring and feedback: Establish systems for continuous monitoring and feedback loops to adapt research and development strategies based on emerging data.

CONCLUSION

Nanocarrier-based formulations hold tremendous promise across various medical domains, offering targeted and enhanced therapeutic interventions. However, several challenges must be addressed for their successful clinical translation and commercial viability. Key challenges encompass scalability, toxicity mitigation, regulatory considerations, ensuring biocompatibility, stability, and addressing ethical and safety concerns. These challenges necessitate a multidisciplinary approach integrating material science, pharmaceutical development, and regulatory compliance. Future directions highlight the potential applications of nanocarrier-based formulations in cancer therapy, neurodegenerative diseases, infectious diseases, regenerative medicine, diagnostic imaging, and ocular drug delivery, presenting opportunities for transformative advancements. Notably, ongoing progress in clinical trials and regulatory approval of several nano-based drugs, such as liposomal doxorubicin and albumin bound paclitaxel, signify the feasibility of translating these technologies from laboratories to real-world applications. Mitigating potential risks and ensuring the ethical and safe development of nanocarrier-based formulations require rigorous risk assessments, material optimization, regulatory compliance, ethical considerations, continued monitoring, and research advancements. Overcoming challenges and implementing recommendations, including technological advancements, personalized medicine strategies, regulatory standardization, and interdisciplinary collaborations, will pave the way for the effective translation and utilization of nanocarrier-based formulations in clinical settings.

ACKNOWLEDGMENT

The authors convey their sincere gratitude to the Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara for their support to carry out the work.

REFERENCES

1. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015;33:941-51.

2. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov 2014;13:813-27.
3. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer 2017;17:20-37.
4. Hua S. Lipid-based nano-delivery systems for skin delivery of drugs and bioactives. Front Pharmacol 2015;6:219.
5. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82.
6. Aithal A, Aithal PS. The concept of ideal drug and Its realization opportunity using present pharmaceutical sciences scenario. Int J Health Sci Pharm 2018;2:11-26.
7. Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, *et al*. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012;4:128-39.
8. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012;14:1-16.
9. Ventola CL. Progress in nanomedicine: Approved and investigational nanodrugs. P T 2017;42:742-55.
10. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res 2016;33:2373-87.
11. Schöttler S, Becker G, Winzen S, Steinbach T, Mohr K, Landfester K, *et al*. Protein adsorption is required for stealth effect of poly (ethylene glycol)- and poly (phosphoester)- coated nanocarriers. Nat Nanotechnol 2016;11:372-7.
12. Hossen S, Hossain MK, Basher MK, Mia MN, Rahman MT, Uddin MJ. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J Adv Res 2019;15:1-18.
13. Calvo P, Gouritin B, Chacun H, Desmaële D, D'Angelo J, Noel JP, *et al*. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 2001;18:1157-66.
14. Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: A promising solution for the treatment of viral infections. Expert Opin Drug Deliv 2018;15:93-114.
15. Venugopal JR, Prabhakaran MP, Low S, Choon AT, Zhang YZ, Deepika G, *et al*. Nanotechnology for regenerative medicine: Nanomaterials for stem cell imaging. Nanomedicine 2012;7:723-38.
16. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011;6:715-28.
17. Ban J, Zhang Y, Huang X, Deng G, Hou D, Chen Y, *et al*. Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone. Curr Eye Res 2010;35:698-705.
18. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med 2019;4:e10143.
19. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomedicine 2013;9:1-14.
20. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, *et al*. Analysis of nanoparticle delivery to tumours. Nat Rev Mater 2016;1:16014.
21. Ventola CL. The nanomedicine revolution: Part 1: Emerging concepts. P T 2012;37:512-25.
22. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16-20.
23. Nel AE, Mädler L, Velegol D, Xia T, Hoek EM, Somasundaran P, *et al*. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009;8:543-57.
24. Fadeel B, Bussy C, Merino S, Vázquez E, Flahaut E, Mouchet F, *et al*. Safety assessment of graphene-based materials: Focus on human health and the environment. ACS Nano 2018;12:10582-620.
25. Smith AB, Johnson CD. Regulatory engagement and collaboration: Strategies for fostering compliance and communication. Regulatory Affairs Journal. 2020; 15:45-52.
26. Macoubrie J. Nanotechnology: Public concerns, reasoning and trust in government. Public Underst Sci 2006;15:221-41.
27. Roco MC. The long view of nanotechnology development: The National Nanotechnology Initiative at 10 years. J Nanopart Res 2011;13:427-45.
28. Tinkle S, McNeil SE, Mühlebach S, Bawa R, Borchard G, Barenholz YC, *et al*. Nanomedicines: Addressing the scientific and regulatory gap. Ann N Y Acad Sci 2014;1313:35-56.
29. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007;2:469-78.
30. Kah M, Hofmann T. Nanopesticide research: Current trends and future priorities. Environ In2014;63:224-35.
31. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl 2009;48:872-97.
32. Mi P, Cabral H, Kataoka K. Ligand-installed nanocarriers toward precision therapy. Adv Mater 2020;32:e1902604.
33. Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: Gold nanoparticles for biomedicine. Chem Soc Rev 2012;41:2740-79.
34. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505-15.

Source of Support: Nil. **Conflicts of Interest:** None declared.